Loading
Raloxifene (Evista) is an osteoporosis tablet that also lowers the chance of developing invasive breast cancer in postmenopausal women at higher risk, with fewer womb-cancer problems than tamoxifen.
Raloxifene was approved in December 1997 for treatment and prevention of postmenopausal osteoporosis and in September 2007 for reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk of breast cancer, on the MORE, CORE and RUTH trials and the head-to-head STAR trial (NSABP P-2), in which raloxifene was about as effective as tamoxifen against invasive breast cancer with fewer uterine cancers and thromboembolic events but less protection against non-invasive disease. It does not treat breast cancer or reduce recurrence. Venous thromboembolism and fatal stroke in women with coronary disease carry a boxed warning.
Oestrogen receptor agonist in bone and antagonist in breast and uterus; lowers the incidence of ER-positive invasive breast cancer. Connects to Estrogen receptor (ERα).
1.Raloxifene acts on Estrogen receptor (ERα), the hormone receptor or the enzyme that makes the hormone.
| Region | Year | Indication |
|---|---|---|
| US | 1997 | Treatment and prevention of postmenopausal osteoporosis |
| US | 2007 | Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Raloxifene" OR ABSTRACT:"Raloxifene" OR TITLE:"Evista" OR ABSTRACT:"Evista") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Raloxifene, not a curated reading list.
Shares Chemoprevention & risk-reducing surgery, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag prevention.
Shares Tamoxifen, Eli Lilly (incl. Loxo), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Tamoxifen and the tag prevention.
Shares Tamoxifen and the tag prevention.
Shares Tamoxifen, Chemoprevention & risk-reducing surgery, Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs).
Shares Chemoprevention & risk-reducing surgery and the tag prevention.
Shares Tamoxifen, Eli Lilly (incl. Loxo), Endocrine therapy (SERMs, AIs, SERDs).
Shares Chemoprevention & risk-reducing surgery, Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.